Weekly fungal diagnostics update – April/May 2026
Date: 5 May 2026
This week’s update highlights advances across fungal diagnostics, particularly in Aspergillus testing, emerging biomarkers, molecular diagnostics, and practical limitations of current methods. Several papers reinforce a key theme: no single test is sufficient — integrated diagnostics remain essential.
Key points
- New evidence supports tracheobronchial aspirate galactomannan in lung transplant recipients.
- Pentraxin 3 emerges as a promising biomarker for invasive pulmonary aspergillosis.
- Molecular and rapid diagnostics continue to improve speed, but interpretation challenges remain.
- Diagnostic pitfalls (e.g. cross-reactivity, morphology limits) remain clinically important.
- Diagnostics are increasingly focused on both detection and resistance.
🧪 Biomarkers and non-culture diagnostics
Pentraxin 3 for invasive pulmonary aspergillosis
PMID: 42054395
This prospective multicentre study highlights pentraxin 3 as a promising biomarker in plasma and bronchoalveolar lavage fluid, particularly in non-neutropenic patients where diagnosis can be more difficult.
Tracheobronchial aspirate galactomannan (GALACTBAS study)
PMID: 42059612
Strong diagnostic performance was reported (sensitivity 95.2%, specificity 92%, AUC 0.97), supporting use in lung transplant recipients.
Emerging metabolic biomarkers in allergic bronchopulmonary aspergillosis
PMID: 42049521
Arachidonic acid metabolite profiles may help distinguish allergic bronchopulmonary aspergillosis from severe asthma, though this remains an emerging research area.
Takeaway: Biomarkers are expanding beyond galactomannan and beta-D-glucan, but are best used in combination with other diagnostics.
🧬 Molecular and rapid diagnostics
Metagenomic next-generation sequencing in mixed infection
PMID: 41723970
Demonstrates rapid identification of multiple pathogens in a complex pulmonary infection (including Aspergillus and Mucorales), highlighting the potential of mNGS in difficult cases.
Rapid LAMP-based susceptibility testing for Aspergillus fumigatus
PMID: 41831694
Shows potential for faster detection of azole resistance, an increasingly important clinical issue.
Dual-target RPA-lateral flow detection (Fusarium keratitis)
PMID: 41651440
Illustrates the growing role of rapid molecular + lateral flow hybrid diagnostics.
Takeaway: Molecular diagnostics are increasingly rapid and sensitive, but standardisation and interpretation remain challenges.
🧫 Blood culture and Candida diagnostics
Cobas ePlex fungal blood culture identification panel
PMID: 42063979
Demonstrates strong performance for rapid species identification in bloodstream infections.
Cross-reactivity in BIOFIRE FilmArray panel
PMID: 42059605
Highlights diagnostic confusion between Candida tropicalis and Candida parapsilosis.
Rapid phenotypic identification of Candida albicans
PMID: 41880733
Evaluates practical lab methods compared with PCR.
Takeaway: Rapid panels are transforming candidemia management, but confirmation and clinical context remain essential.
⚠️ Diagnostic limitations and pitfalls
Accuracy of morphology-based fungal diagnosis in lung pathology
PMID: 41248033
Shows that morphology alone may not reliably distinguish fungal genera, reinforcing the need for microbiological or molecular confirmation.
Laboratory innovations in invasive mould diagnostics (review)
PMID: 41173342
Summarises emerging targets including siderophores, urinary glycans and molecular diagnostics.
Takeaway: Diagnostic errors remain possible — especially when relying on a single modality.
🔬 Emerging themes
1. Diagnostics are layered, not replaced
No single test dominates. Optimal diagnosis requires combining:
- Imaging
- Biomarkers
- Culture
- Molecular methods
- Clinical judgement
2. Resistance is becoming part of diagnosis
New tools are beginning to answer not just “what is present?” but also “will treatment work?”.
3. Non-invasive diagnostics are expanding
Blood-based and airway-based biomarkers continue to improve, with the aim of reducing reliance on invasive sampling.
Clinical bottom line
Fungal diagnostics are improving rapidly, but remain complex. The most reliable approach continues to be integrated, multi-modal testing interpreted within the clinical context. Emerging biomarkers and molecular tools are promising, but do not replace established methods.